NCT07789119 Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract
| NCT ID | NCT07789119 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Urothelial Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 50,000 participants |
| Start Date | 2026-09-10 |
| Primary Completion | 2036-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50,000 participants in total. It began in 2026-09-10 with a primary completion date of 2036-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To collect, process, store, and study biological samples and related clinical and imaging data from participants with known or suspected urothelial carcinoma or another related malignancy of the urinary tract.
Eligibility Criteria
Eligibility Criteria Participants must meet all of the following criteria for enrollment: 1. Age 18 years or older at the time of consent. 2. Known or suspected urothelial carcinoma or other related malignancy of the urinary tract for which biospecimen and associated clinical data collection is relevant to the objectives of this protocol. This may include patients undergoing diagnostic evaluation for a lesion, mass, abnormal cytology, or other clinical finding concerning for malignancy. 3. Undergoing evaluation, treatment, surveillance, follow-up care, or clinically indicated procedures at The University of Texas M.D. Anderson Cancer Center, including Houston Area Locations. 4. Able to understand and personally provide informed consent. 5. Willing to allow prospective collection, banking, storage, and research use of biospecimens and associated clinical information as described in the informed consent document. Exclusion Criteria 1. Age younger than 18 years. 2. Unable to understand the study information or unable to personally provide informed consent. 3. Declines participation. 4. No known or suspected urothelial carcinoma or other related malignancy of the urinary tract, and no clinical circumstance in which enrollment under this protocol is relevant to the study objectives. 5. Clinical, operational, or safety circumstances that make enrollment or research collection inappropriate or not feasible in the judgment of the treating clinical team or study investigators. Examples may include urgent clinical priorities, insufficient residual specimen after diagnostic needs are met, inability to safely obtain research specimens during a clinically indicated procedure, or inability to complete consent appropriately. 6. Prisoners or other populations requiring additional regulatory protections not specifically approved under this protocol.
Contact & Investigator
Byron Lee, MD
PRINCIPAL INVESTIGATOR
UT MD Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT07789119 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Urothelial Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07789119 currently recruiting?
Yes, NCT07789119 is actively recruiting participants. Contact the research team at BHLee@mdanderson.org for enrollment information.
Where is the NCT07789119 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT07789119 clinical trial?
NCT07789119 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Byron Lee, MD at UT MD Anderson Cancer Center. The trial plans to enroll 50,000 participants.